Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
about
Phosphate binders for the treatment of chronic kidney disease: role of iron oxyhydroxideManaging hyperphosphatemia in patients with chronic kidney disease on dialysis with ferric citrate: latest evidence and clinical usefulnessPhosphate binders in chronic kidney disease: a systematic review of recent data.Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.Novel Therapeutic Options for the Treatment of Mineral Metabolism Abnormalities in End Stage Renal Disease.Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Iron Therapy Challenges for the Treatment of Nondialysis CKD PatientsEfficacy and safety of sucroferric oxyhydroxide compared with sevelamer hydrochloride in Japanese haemodialysis patients with hyperphosphataemia: A randomized, open-label, multicentre, 12-week phase III study.Advances in pharmacotherapy for hyperphosphatemia in renal disease.A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.Emerging drugs for the treatment of kidney disease-induced anemia.Treating hyperphosphatemia - current and advancing drugs.Phosphate binders in patients with chronic kidney disease.Treatment of renal anemia: Erythropoiesis stimulating agents and beyond.Ferritin Elevation and Improved Responsiveness to Erythropoiesis-Stimulating Agents in Patients on Ferric Citrate Hydrate.One-year efficacy and safety of the iron-based phosphate binder sucroferric oxyhydroxide in patients on peritoneal dialysis.Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.Efficacy and Safety of Sucroferric Oxyhydroxide and Calcium Carbonate in Hemodialysis Patients.A regenerable potassium and phosphate sorbent system to enhance dialysis efficacy and device portability: a study in awake goats.Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.Adherence rates to ferric citrate as compared to active control in patients with end stage kidney disease on dialysis.Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
P2860
Q26764806-DF875E2B-D470-48FE-9FFD-2EE52E20BBC2Q26786000-92EFB3E2-6166-4A3A-BB9F-BCE98D04EB14Q31039292-3BFD02F0-EBF6-4D93-A5F9-990B59AC5366Q33840398-7DA03B04-5FE5-4DFC-B04D-D12BC07A4638Q36225208-73B593E3-886A-45C0-9DE9-5FBDCF8150E1Q36322947-2863093C-0CCE-467F-8341-349C82C799D3Q37069943-483BCABF-A3B1-41A7-BB8C-576F1C13F66CQ37696553-47791601-DCB0-4948-8C98-6A3409CEA6AFQ38587575-31DEBC0A-EC8D-4DC8-A924-C9E4541F416BQ38741675-1DDE00FE-90F1-4F15-AF8B-818F4A01D6F5Q38819231-BEB113C6-65EF-478A-9AAF-4DD380AA28D3Q38828902-DAF64650-ED78-4D57-BDD2-5CD5533D2CA0Q38930912-A274F5B4-5A0D-4B46-8C3F-A6F242BD4051Q38958363-7E6E8716-7507-4B73-A5D0-E1C9E924FE4EQ39155279-BC63B978-D3A6-405C-ACD8-77E9A85D27BEQ41387413-AE70BE10-B86D-41B8-89D4-6CA13B4D5454Q45853530-462A203B-F7E7-40EC-87D0-B464D6EC80DCQ46034498-C832846E-54E8-451B-BF81-AAA3AB7DB29FQ46547077-62C23560-6353-4AA3-81F2-49E968FA0B57Q49279657-D6726B82-13AF-4C25-A46C-2E53673575AFQ51318751-68517486-0D8E-4348-951C-F9517441F332Q51743408-803F51D0-0DA4-42C9-98F1-44BF9F821195Q53775627-5F29FB92-BE64-470E-912B-CC64A160E0E2Q55347421-09C578F9-DC7A-4B26-9F88-C512515BAF82
P2860
Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@ast
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@en
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@nl
type
label
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@ast
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@en
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@nl
prefLabel
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@ast
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@en
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@nl
P2093
P2860
P356
P1476
Long-term effects of the iron- ...... ydroxide, in dialysis patients
@en
P2093
Adrian C Covic
Anjay Rastogi
Bruce Spinowitz
Edward M F Chong
Johannes F E Mann
Jürgen Floege
Laura J Lisk
Markus Ketteler
Stuart M Sprague
Sucroferric Oxyhydroxide Study Group
P2860
P304
P356
10.1093/NDT/GFV006
P407
P577
2015-02-16T00:00:00Z